Royal College of Surgeons in Ireland
Adoptive immunotherapy and high-risk myeloma.pdf (351.29 kB)
Download file

Adoptive immunotherapy and high-risk myeloma

Download (351.29 kB)
journal contribution
posted on 2023-06-01, 13:35 authored by Catherine DuaneCatherine Duane, Michael O'Dwyer, Siobhan GlaveySiobhan Glavey

Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma. 



The original article is available at

Published Citation

Duane C, O'Dwyer M, Glavey S. Adoptive immunotherapy and high-risk myeloma. Cancers (Basel). 2023;15(9):2633.

Publication Date

6 May 2023

PubMed ID



  • Beaumont Hospital
  • Pathology




  • Published Version (Version of Record)